Comparative Pharmacology
Head-to-head clinical analysis: PROCAN versus PROCANBID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROCAN versus PROCANBID.
PROCAN vs PROCANBID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Procainamide is a class Ia antiarrhythmic agent that blocks sodium channels, slowing conduction velocity and prolonging the refractory period. It also has weak anticholinergic effects.
Class Ia antiarrhythmic agent; inhibits sodium channels, slowing conduction velocity, increasing effective refractory period, and suppressing automaticity.
250 mg orally every 6 hours; extended-release product: 500 mg orally every 6 hours.
Procainamide extended-release (Procanbid) is dosed based on ideal body weight. Typical adult dose: 500 mg to 1500 mg orally every 12 hours. Maximum dose: 3000 mg/day. Dose should be titrated to achieve therapeutic plasma procainamide and NAPA levels.
None Documented
None Documented
Procainamide: 2.5-4.7 hours (increased to 4-6 hours in elderly or heart failure; prolonged in renal impairment). NAPA: 6-9 hours (active metabolite). Clinical context: Therapeutic monitoring requires measurement of both parent drug and metabolite due to NAPA's antiarrhythmic activity.
Terminal elimination half-life: 2.5-4.7 hours (procainamide) with normal renal function; clinical context: prolonged in renal impairment (up to 14 hours) and heart failure; NAPA half-life: 6-8 hours.
Renal: 50-67% as unchanged drug and major metabolite N-acetylprocainamide (NAPA). Biliary/fecal: <10%.
Renal excretion: 50-60% unchanged; hepatic metabolism to N-acetylprocainamide (NAPA) with further renal elimination; total renal elimination of procainamide and NAPA >80%.
Category C
Category C
Class Ia Antiarrhythmic
Class Ia Antiarrhythmic